BCYCBicycle Therapeutics Plc - ADR
BCYC
Bicycle Therapeutics Plc - ADR930
Mkt Cap
$239.66MVolume
400,434.0052W High
$9.3652W Low
$4.24PE Ratio
-1.51BCYC Fundamentals
Price
$4.80Prev Close
$4.72Open
$4.6850D MA
$5.02Beta
1.25Avg. Volume
410,290.63EPS (Annual)
-$3.17P/B
0.55Rev/Employee
$252,623.69$120.63
Bicycle Therapeutics (NASDAQ:BCYC) Rating Lowered to "Sell" at Wall Street Zen
Wall Street Zen cut shares of Bicycle Therapeutics from a 'hold' rating to a 'sell' rating in a research report on Saturday...
MarketBeat·23h ago
Bicycle Therapeutics (NASDAQ:BCYC) Announces Earnings Results, Misses Estimates By $0.25 EPS
Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts...
MarketBeat·2d ago
Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results
Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today...
Business Wire·3d ago
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Shares of Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the eleven brokerages that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell re...
MarketBeat·3d ago
Bicycle Therapeutics (BCYC) to Release Quarterly Earnings on Thursday
Bicycle Therapeutics (NASDAQ:BCYC) will be releasing its Q1 2026 earnings before the market opens on Thursday, April 30. (View Earnings Report at...
MarketBeat·10d ago
Bicycle Therapeutics Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting
Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today...
Business Wire·12d ago
Bicycle Therapeutics Provides Update on Nuzefatide Pevedotin and EphA2 Pipeline at the AACR Annual Meeting 2026
Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced updates from its EphA2 pipeline at the American Association for Cancer Research (AACR) Annual...
Business Wire·13d ago
Wall Street Analysts Believe Bicycle Therapeutics (BCYC) Could Rally 137.88%: Here's is How to Trade
The mean of analysts' price targets for Bicycle Therapeutics (BCYC) points to a 137.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks·17d ago
Morgan Stanley Has Lowered Expectations for Bicycle Therapeutics (NASDAQ:BCYC) Stock Price
Morgan Stanley lowered their target price on shares of Bicycle Therapeutics from $13.00 to $12.00 and set an "equal weight" rating for the company in a report on Wednesday...
MarketBeat·25d ago
Bicycle Therapeutics (NASDAQ:BCYC) CEO Sells $29,297.97 in Stock
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC - Get Free Report) CEO Kevin Lee sold 5,967 shares of the firm's stock in a transaction that occurred on Thursday, April 2nd. The shares were sold...
MarketBeat·26d ago
<
1
2
...
>